The global GLP-1 market size is set to grow significantly, from USD 49.3 billion in 2024 to USD 157.5 billion by 2035, achieving a robust CAGR of 11.1% over the forecast period. This growth is fueled by the increasing prevalence of metabolic disorders, rapid adoption of GLP-1 receptor agonists across multiple therapeutic indications, and technological advancements in drug formulations and delivery systems. The expansion of the market size reflects the shift toward targeted therapies offering improved clinical outcomes and better patient compliance.

Roots Analysis’s latest report, “GLP-1 Market,” provides a deep dive into evolving market dynamics, identifying key trends, innovations, and strategic initiatives shaping the future. It examines how pharmaceutical companies are capitalizing on the growing GLP1 market size through development of novel multi-agonist therapies, diversification into obesity and NASH treatments, and a strong focus on oral GLP-1 products.

The study also covers emerging opportunities arising from the potential application of GLP-1-based therapies in neurodegenerative conditions like Alzheimer’s disease and the broader expansion of metabolic syndrome management strategies.

Competitive Landscape

Key players driving the GLP-1 industry forward include AstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Gmax Biopharm, Hanmi Pharmaceutical, Innogen, Novo Nordisk, PegBio, Pfizer, QL Biopharma, Roche, Sanofi, Sciwind Biosciences, Tonghua Dongbao Pharmaceutical, Viking Therapeutics, Vivani, and vTv Therapeutic.

These companies are pursuing aggressive R&D strategies, expanding their clinical pipelines, and forming strategic alliances to consolidate their market positions. The competition is especially intense in next-generation dual- and tri-agonist categories, where therapeutic differentiation and innovation speed are critical to success.

Market Segmentation

The market has been segmented as follows to reflect the key areas impacting the GLP-1 market size:

• By Type of Molecule:
  Includes biologics such as injectable proteins and small molecules, offering expanded choices for different patient groups.
• By Active Compound Used:
  Major active agents like dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, and tirzepatide form the backbone of current and future GLP-1-based therapies.
• By Type of GLP-1 Agonist Drugs:
  Divided into long-acting and short-acting formulations, addressing different dosing frequencies and patient adherence concerns.
• By Type of Agonist:
  Single agonists remain dominant, but dual (GLP-1/GIP) and tri-agonists (GLP-1/GIP/glucagon) are gaining significant traction in clinical pipelines.
• By Route of Administration:
  Oral administration is emerging as a game-changer, improving convenience over traditional parenteral routes and thus expanding the GLP-1 market size.
• By Target Indication:
  Apart from type 2 diabetes, GLP-1 therapies are increasingly being utilized in the management of obesity, Alzheimer’s disease, sleep apnea, and NASH.
• By Geography:
  North America (US, Canada) remains the largest contributor to the GLP-1 market size, followed by major markets in Europe (Germany, UK, France, Italy, Spain, Netherlands) and rapid growth regions like Asia Pacific, Latin America, and the Middle East and North Africa.

Research Methodology

The analysis relies on a robust blend of primary interviews with clinical researchers, endocrinologists, and pharma executives, combined with extensive secondary research through scientific literature, market intelligence reports, and commercial databases. Multi-parameter modeling was used to forecast the market size, factoring in key variables such as drug approvals, technological innovations, pricing trends, and regulatory policies. Rigorous data validation ensured the robustness of insights delivered in the study.

Author: jespaul606